Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Expression of FUNDC1 and HIF-1α in EC. Relationship of FUNDC1 and HIF-1α in the EC TCGA cohort ( A ) and clinical cohort ( B ). Serial sections of 288 endometrial carcinoma tissues from our cohort were stained with FUNDC1 and HIF-1α antibodies. Representative image of low ( C ) and high ( D ) FUNDC1 expression. Representative image of low ( E ) and high ( F ) HIF-1α expression.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Expressing, Staining

Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Correlation between FUNDC1 and HIF-1α expression and clinicopathological features of EC.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Kaplan-Meier curves for overall survival (OS) and progression-free survival (PFS) in EC patients. Comparison of OS (A) and PFS (D) between high FUNDC1 and low FUNDC1 groups in TCGA. Comparison of OS (B) and PFS (E) between high and low HIF-1α groups in TCGA. Comparison of OS (C) and PFS (F) between high and low HIF-1α and FUNDC1 co-expression groups in TCGA. Comparison of OS (G) and PFS (J) between high FUNDC1 and low FUNDC1 groups in clinical data. Comparison of OS (H) and PFS (K) between high and low HIF-1α groups in clinical data. Comparison of OS (I) and PFS (L) between high and low HIF-1α and FUNDC1 co-expression groups in clinical data.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Comparison, Expressing

Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Univariate and multivariate analysis for overall survival.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Univariate and multivariate analysis for progression-free survival.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Expressing

Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Silencing of FUNDC1 inhibits the viability and metastasis of EC cells. (A) For stable FUNDC1 knockdown, EC cells were transduced separately with two shRNAs (shFUNDC1#1 and shFUNDC1#2) that target FUNDC1 mRNA. Western blotting was used to detect the expression of FUNDC1 levels. (B) Cell growth rate was suppressed by FUNDC1 knockdown in Ishikawa and HEC-1B cells, as measured by CCK8 assay. (C) Cell invasion of HEC-1B and HEC-1B-shFUNDC1#1 cells. Representative images of cell invasion are shown on the right side, scale bar: 200 μm. (D) Wound healing assays were performed to characterize changes in the migration of HEC-1B, HEC-1B-shFUNDC1#1, Ishikawa and Ishikawa-shFUNDC1#1 cells. Scale bar: 100 μm. Results are expressed as mean ± SD of three independent experiments. * P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Knockdown, Western Blot, Expressing, CCK-8 Assay, Migration

Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Relationship between FUNDC1 expression and chemoresistance. A comparison of FUNDC1 (A) and HIF-1α (B) IHC scores of EC patients with recurrence within 1 year after chemotherapy and those without recurrence. CCK8 assays were performed before and after retreatment with different concentrations of CBP for 48 h in HEC-1B cells (C) and Ishikawa cells (E) , as well as their FUNDC1-silenced cells. Different concentrations of PTX were used to treat HEC-1B, HEC-1B-shFUNDC1#1/2 cells (D) , Ishikawa and Ishikawa-shFUNDC1#1/2 cells (F) . Then, after 48 h, growth inhibition was assessed. * P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Expressing, Comparison, Inhibition

Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Inhibition of FUNDC1 impairs the expression of LC3B and HIF-1α, and decreases mitophagy in EC cells. (A) Western blot analysis was conducted to determine the protein levels of FUNDC1, HIF-1α, and LC3B, and the ratio of LC3BII to LC3BI. Quantitative analysis of western blots for FUNDC1 (B) , HIF-1α (C) , and LC3BII/LC3BI (D) . (E) HEC-1B and HEC-1B-shFUNDC1#1/2 cells were stained with both MitoTracker Red and LysoTracker Green, and were observed by fluorescence microscopy. The number of yellow puncta (mitochondria-lysosome colocalization) represents the formation of autolysosomes with internalized mitochondria. (F) The mitochondrial membrane potential of HEC-1B and FUNDC1-silenced HEC-1B cells is represented by JC-1 staining. Representative fluorescence images of JC-1 aggregates (red) and JC-1 monomers (green) are shown in the figure. (G) Quantification of the percentage of mitochondria-lysosome colocalization for HEC-1B and HEC-1B-shFUNDC1#1/2 cells. (H) Quantification of mitochondrial membrane potential (JC-1 aggregate/monomer ratio) for HEC-1B and HEC-1B-shFUNDC1#1/2 cells. Scale bar: 50 μm. n=3 per group. Data represent the mean ± SD. * P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Inhibition, Expressing, Western Blot, Staining, Fluorescence, Microscopy, Membrane

Journal: Journal of Cancer

Article Title: FUNDC1 predicts Poor Prognosis and promotes Progression and Chemoresistance in Endometrial Carcinoma

doi: 10.7150/jca.96877

Figure Lengend Snippet: Functional enrichment analysis of FUNDC1-related genes and the relationship between FUNDC1 mRNA expression and immune infiltration in EC. KEGG ( A ) and GO ( B ) analyses for the top 930 FUNDC1-related genes in EC. The roles of FUNDC1 in EC based on GSEA ( C-E ). Expression of FUNDC1 was involved in endometrial cancer ( C ), NOD-like receptor signaling pathway ( D ) and immune system cytokine signaling ( E ). ( F ) Correlation between 24 immune cell abundances and FUNDC1 expression levels, with dot size indicating Spearman R value. Diagrams show correlation between NK cells ( G ), Th2 cells ( H ) infiltration levels and FUNDC1 expression. ( I ) Correlation analysis of FUNDC1 expression and immune infiltration in EC. * P < 0.05; ** P < 0.01; *** P < 0.001.

Article Snippet: Short hairpin RNA (shRNA) was used to silence the expression of FUNDC1 by infecting with recombinant lentivirus particles encoding shRNA targeting FUNDC1 (shFUNDC1#1: 5'-GAAAGTGATGACGACTCTTAT-3'; shFUNDC1#2: 5'-GATTAAGAAACGAGCGAACAA-3', Beijing SyngenTech Co., LTD).

Techniques: Functional Assay, Expressing

Journal: Brain

Article Title: PAK2 is necessary for myelination in the peripheral nervous system

doi: 10.1093/brain/awad413

Figure Lengend Snippet: Intraneural lentivirus delivery restores PAK2 expression in Schwann cells of scPak2 −/− sciatic nerves in vivo . ( A ) A sciatic nerve from a 3-day-old scPak2 −/− mouse was surgically exposed and locally injected with 2 μl lentivirus particles at 10 10 cfu/ml of GFP-only, GFP-WT-PAK2 (wild-type PAK2) or GFP-K278R-PAK2 (kinase-dead PAK2 mutation). The contralateral sciatic nerve was injected with 2 μl PBS as a control. At P30, the sciatic nerves were dissected. After fixation, teased nerve fibres were stained with myelin basic protein (MBP) antibody and imaged. ( B ) The MBP fluorescence intensity of each internode within nerve fibres was quantified and the average intensity for each mouse was calculated. The intensity of MBP was significantly increased in GFP-positive fibres (between arrowheads) from scPak2 −/− nerves transfected with GFP- WT-Pak2 lentivirus, but not GFP-positive fibres from scPak2 −/− nerves transfected with GFP- K278R-Pak2 lentivirus, compared with fibres (between arrows) in scPak2 −/− nerve fibres transfected with GFP-only lentivirus (mean ± SD, P < 0.001, n = 10–20 fibres per mouse, n = 5 mice per group). ( C ) Internodal lengths of each nerve fibre were quantified. The average internodal length increased by 40% in scPak2 −/− nerves treated with GFP- WT-Pak2 lentivirus (264.2 ± 30 μm for internodes in scPak2 −/− nerves injected with GFP- WT-Pak2 lentivirus versus 186.9 ± 14 μm for internodes in scPak2 −/− nerve fibres injected with GFP-only lentivirus, mean ± SD, P < 0.01, 10–20 fibres per mouse, n = 5 mice per group). This rescue was not observed in nerve fibres injected with kinase-dead Pak2 mutation. DIC = differential interference contrast; GFP = green fluorescent protein; SD = standard deviation.

Article Snippet: A fine glass needle (Fivephoton Biochemicals) containing 2 μl of 10 10 cfu/ml lentivirus particles mixed with 0.01% Fast Green was injected into the sciatic nerve using a micromanipulator until the nerves appeared green.

Techniques: Expressing, In Vivo, Injection, Mutagenesis, Control, Staining, Fluorescence, Transfection, Standard Deviation

Journal: Molecular Cancer

Article Title: miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1

doi: 10.1186/s12943-017-0625-8

Figure Lengend Snippet: Identification of TIA1 as a miR-19a target. a Schematic description of the hypothetical duplex formed by the interactions between the binding site in the TIA1 3’-UTR and miR-19a. The miR-19a seed sequence and the seed sequence binding sites in the TIA1 3’-UTR are indicated in red . All nucleotides of the seed sequence of the binding site are conserved in several species, including human, mouse, rat and rabbit. The predicted free energy values of the hybrids are indicated. b Quantitative RT-PCR analysis of miR-19a expression levels in the same 16 pairs of CRC and normal tissue samples. c Pearson’s correlation scatter plot of the fold changes of miR-19a and TIA1 protein in human CRC tissue pairs. *** P < 0.001

Article Snippet: For miRNA pull-down, SW480 cells which were transfected with biotinylated miR-19a (miR-19a probe) or control probe (Genescript, Nanjing, China) were harvested in lysis buffer (20 mM Tris pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40 and 1 U/ul Recombinant RNAse inhibitor (TaKaRa)), and the total RNA was pretreated with DNaseI and then heated at 65 °C for 5 min, followed by an instant ice bath.

Techniques: Binding Assay, Sequencing, Quantitative RT-PCR, Expressing

Journal: Molecular Cancer

Article Title: miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1

doi: 10.1186/s12943-017-0625-8

Figure Lengend Snippet: miR-19a directly regulates TIA1 expression at the post-transcriptional level. a Quantitative RT-PCR analysis of miR-19 levels in SW480, Caco2 and HT-29 cells. miR-19 level of SW480 was set as control. b Western blot analysis of TIA1 protein levels in SW480, Caco2 and HT-29 cells. TIA1 level of SW480 was set as control. c Pearson’s correlation scatter plot of the level of miR-19 and TIA1 protein in SW480, Caco2 and HT-29 cells. d Quantitative RT-PCR analysis of miR-19a levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor. e and f Western blot analysis of TIA1 protein levels in SW480, Caco2 and HT-29 cells transfected with control mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor. e : representative images; f : quantitative analysis. g Quantitative RT-PCR analysis of TIA1 and GAPDH mRNA levels in SW480 after pulling down with control probe or miR-19a probe; h Quantitative RT-PCR analysis of miR-19a and miR-22 levels in SW480 after pulling down with control probes or two TIA1 mRNA probes; i The relative luciferase activities in SW480 transfected with wild type or mutant TIA1 3’-UTR. * P < 0.05; ** P < 0.01; *** P < 0.001

Article Snippet: For miRNA pull-down, SW480 cells which were transfected with biotinylated miR-19a (miR-19a probe) or control probe (Genescript, Nanjing, China) were harvested in lysis buffer (20 mM Tris pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40 and 1 U/ul Recombinant RNAse inhibitor (TaKaRa)), and the total RNA was pretreated with DNaseI and then heated at 65 °C for 5 min, followed by an instant ice bath.

Techniques: Expressing, Quantitative RT-PCR, Control, Western Blot, Transfection, Luciferase, Mutagenesis

Journal: Molecular Cancer

Article Title: miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1

doi: 10.1186/s12943-017-0625-8

Figure Lengend Snippet: c-MYC, miR-19a, TIA1 and PDCD4 form a regulatory axis in CRC. a and b Western blot analysis of c-Myc and TIA1 protein levels in SW480 cells transfected with control siRNA, si-c-Myc, si-c-Myc plus miR-19a mimic, control plasmid, c-Myc plasmid, or c-Myc plasmid plus miR-19a inhibitor. a : representative images; b : quantitative analysis. c Quantitative RT-PCR analysis of miR-19a levels in SW480 cells transfected with control siRNA, si-c-Myc, si-c-Myc plus miR-19a mimic, control plasmid, c-Myc plasmid, or c-Myc plasmid plus miR-19a inhibitor. d and e Western blot analysis of TIA1 and PDCD4 protein levels in SW480 cells transfected with control mimic, miR-19a mimic, miR-19a mimic plus TIA1 plasmid, control inhibitor, miR-19a inhibitor, or miR-19a inhibitor plus si-TIA1. d : representative images; e : quantitative analysis. f Quantitative RT-PCR analysis of PDCD4 mRNA levels in SW480 cells transfected with control mimic, miR-19a mimic, miR-19a mimic plus TIA1 plasmid, control inhibitor, miR-19a inhibitor, or miR-19a inhibitor plus si-TIA1. ND: Non-Detectable. * P < 0.05; ** P < 0.01; *** P < 0.001

Article Snippet: For miRNA pull-down, SW480 cells which were transfected with biotinylated miR-19a (miR-19a probe) or control probe (Genescript, Nanjing, China) were harvested in lysis buffer (20 mM Tris pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40 and 1 U/ul Recombinant RNAse inhibitor (TaKaRa)), and the total RNA was pretreated with DNaseI and then heated at 65 °C for 5 min, followed by an instant ice bath.

Techniques: Western Blot, Transfection, Control, Plasmid Preparation, Quantitative RT-PCR

Journal: Molecular Cancer

Article Title: miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1

doi: 10.1186/s12943-017-0625-8

Figure Lengend Snippet: miR-19a promotes CRC cell proliferation by targeting TIA1. a Cell proliferation assays (CCK-8) were performed 12, 24, 36, 48 and 60 h after the transfection of SW480 cells with equal doses of control mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor. b and c Cell proliferation assays (EdU) were performed in SW480 cells transfected with equal doses of control mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor. b : representative images; c : quantitative analysis. d Cell proliferation assays (CCK-8) were performed 12, 24, 36 and 48 and 60 h after transfection of SW480 cells with equal doses of control mimic plus control plasmid, miR-19a mimic plus control plasmid, control mimic plus TIA1 overexpression plasmid, or miR-19a mimic plus TIA1 overexpression plasmid. e and f Cell proliferation assays (EdU) were performed in SW480 cells transfected with equal doses of control mimic plus control plasmid, miR-19a mimic plus control plasmid, control mimic plus TIA1 overexpression plasmid, or miR-19a mimic plus TIA1 overexpression plasmid. e : representative images; f : quantitative analysis. ** P < 0.01; *** P < 0.001

Article Snippet: For miRNA pull-down, SW480 cells which were transfected with biotinylated miR-19a (miR-19a probe) or control probe (Genescript, Nanjing, China) were harvested in lysis buffer (20 mM Tris pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40 and 1 U/ul Recombinant RNAse inhibitor (TaKaRa)), and the total RNA was pretreated with DNaseI and then heated at 65 °C for 5 min, followed by an instant ice bath.

Techniques: CCK-8 Assay, Transfection, Control, Plasmid Preparation, Over Expression

Journal: Molecular Cancer

Article Title: miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1

doi: 10.1186/s12943-017-0625-8

Figure Lengend Snippet: miR-19a promotes CRC cell migration by targeting TIA1. a – c Cell migration assays (Transwell) were performed in SW480 cells that were transfected with equal doses of control mimic, miR-19a mimic, control inhibitor or miR-19a inhibitor (upper panel), or with equal doses of control mimic plus control plasmid, miR-19a mimic plus control plasmid, control mimic plus TIA1 overexpression plasmid, or miR-19a mimic plus TIA1 overexpression plasmid (lower panel). a : representative images; b and c : quantitative analysis of the number of migrated cells. * P < 0.05; ** P < 0.01

Article Snippet: For miRNA pull-down, SW480 cells which were transfected with biotinylated miR-19a (miR-19a probe) or control probe (Genescript, Nanjing, China) were harvested in lysis buffer (20 mM Tris pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40 and 1 U/ul Recombinant RNAse inhibitor (TaKaRa)), and the total RNA was pretreated with DNaseI and then heated at 65 °C for 5 min, followed by an instant ice bath.

Techniques: Migration, Transfection, Control, Plasmid Preparation, Over Expression

Journal: Molecular Cancer

Article Title: miR-19a promotes colorectal cancer proliferation and migration by targeting TIA1

doi: 10.1186/s12943-017-0625-8

Figure Lengend Snippet: miR-19a promotes CRC growth in vitro and in vivo by targeting TIA1. a and b Colony formation assays of SW480 cells infected with miR-19a lentivirus, transfected with TIA1 vector or both. a : Representative images of colony formation assays; b : quantitative analysis of the numbers of colonies. c Representative images of tumors from the implanted mice. d and e Quantitative analysis of xenografted tumor volume and weight. d : tumor volume; e : tumor weight. f – h H&E-stained sections and immunohistochemical staining for TIA1 and Ki-67 in tumors from implanted mice. f : representative images; g and h : quantitative analysis. i Working model of the c-Myc-miR-19a-TIA1-PDCD4 regulatory axis in CRC. ** P < 0.01; *** P < 0.001

Article Snippet: For miRNA pull-down, SW480 cells which were transfected with biotinylated miR-19a (miR-19a probe) or control probe (Genescript, Nanjing, China) were harvested in lysis buffer (20 mM Tris pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.5% NP-40 and 1 U/ul Recombinant RNAse inhibitor (TaKaRa)), and the total RNA was pretreated with DNaseI and then heated at 65 °C for 5 min, followed by an instant ice bath.

Techniques: In Vitro, In Vivo, Infection, Transfection, Plasmid Preparation, Staining, Immunohistochemical staining

Journal: International Journal of Molecular Sciences

Article Title: Arsenic Trioxide Suppressed Migration and Angiogenesis by Targeting FOXO3a in Gastric Cancer Cells

doi: 10.3390/ijms19123739

Figure Lengend Snippet: FOXO3a mediated the inhibitory effect of As 2 O 3 on cell migration in vitro. ( A ) The cells transfected into the GFP-labeled virus were observed in white light and green fluorescence after transfection for 48 h (100×). ( B ) qRT-PCR analyses showed FOXO3a mRNA expression of MGC-803 and SGC-7901 cells infected with shFOXO3a or the negative control shRNA. ( C ) Western blotting analysis showed total FOXO3a protein expression of these transfected cells. ( D , E ) Wound healing assays showed the migration distances of transfected cells treated with As 2 O 3 for 24 h (100×). The quantification of migration rates was analyzed respectively. ( F ) Transwell assays showed the migration of these cells treated with As 2 O 3 for 24 h. The quantification of migration cells was performed. Scale bar, 100 µm. All data were obtained from three independent experiments. Compared with the NC group, * p < 0.05, ** p < 0.01, and *** p < 0.001; compared with NC + As 2 O 3 group, # p < 0.05.

Article Snippet: Lentivirus particles encoding shFOXO3a were purchased from GenePharma (Shanghai, China).

Techniques: Migration, In Vitro, Transfection, Labeling, Virus, Fluorescence, Quantitative RT-PCR, Expressing, Infection, Negative Control, shRNA, Western Blot

Journal: International Journal of Molecular Sciences

Article Title: Arsenic Trioxide Suppressed Migration and Angiogenesis by Targeting FOXO3a in Gastric Cancer Cells

doi: 10.3390/ijms19123739

Figure Lengend Snippet: FOXO3a mediated the inhibitory effect of As 2 O 3 on angiogenesis in vitro. ( A ) Tube formation assays detected formed tubes of HUVECs treated with CM from MGC-803 and SGC-7901 cells transfected with negative control shRNA or shFOXO3a. Calculating branch points per field was used to quantify the ability of tube formation. Scale bar, 100 µm. ( B , C ) ELISA analysis detected total VEGF protein secretion in these cells. All data were obtained from three independent experiments. ( D , E ) The expression of MMP9 and VEGF was detected by western blotting. Compared with the NC group, * p < 0.05, ** p < 0.01; compared with NC + As 2 O 3 group, # p < 0.05, ## p < 0.01.

Article Snippet: Lentivirus particles encoding shFOXO3a were purchased from GenePharma (Shanghai, China).

Techniques: In Vitro, Transfection, Negative Control, shRNA, Enzyme-linked Immunosorbent Assay, Expressing, Western Blot

Journal: International Journal of Molecular Sciences

Article Title: Arsenic Trioxide Suppressed Migration and Angiogenesis by Targeting FOXO3a in Gastric Cancer Cells

doi: 10.3390/ijms19123739

Figure Lengend Snippet: As 2 O 3 inhibited gastric tumor growth through regulating FOXO3a. ( A ) The xenografted tumors were formed by subcutaneous injection with shFOXO3a or negative control shRNA MGC-803 cells in nude mice. The tumors were observed after As 2 O 3 treatment. ( B , C ) The tumor volume and weight were respectively measured and statistically analyzed. Compared with the NC group, * p < 0.05, ** p < 0.01; compared with NC + As 2 O 3 group, # p < 0.05, ## p < 0.01.

Article Snippet: Lentivirus particles encoding shFOXO3a were purchased from GenePharma (Shanghai, China).

Techniques: Injection, Negative Control, shRNA